Registration

Webinar: Data Integration, Analysis, and Interpretation of Eight Academic CLARITY-BPA Studies

July 21st , 12 noon EDT

Biomonitoring Resource Center Webinar

This webinar on BPA research is part of a series of webinars organized by the EDC Strategies Partnership, chaired by Sharyle Patton (Commonweal Biomonitoring Resource Center), Jerry Heindel (Commonweal HEEDS, Healthy Environment and Endocrine Disruptor Strategies), and Genon Jensen (HEAL) and coordinated by Hannah Donart (Collaborative on Health and the Environment, a Commonweal program)

Topic:
The BPA Toxicity (CLARITY-BPA) is a comprehensive “industry-standard” Good Laboratory Practice (GLP)-compliant 2-year chronic exposure study of bisphenol A (BPA) toxicity that was supplemented by hypothesis-driven independent investigator-initiated studies. This study was funded and coordinated by the US FDA, the National Toxicology Program, and the National Institute of Environmental Health Sciences, Division of Extramural Research and Training.


Presenters:
Jerry Heindel
will present an overview of the CLARITY-BPA program and an introduction to the current publication, “Data integration, analysis, and interpretation of eight academic CLARITY-BPA studies.”
Gail Prins will present data on the effects of BPA on the prostate and her findings that the prostate stem cells were altered by chronic low-dose BPA exposure which may be the basis for increased cancer risk.
Ana Soto will present an overview of her project which focused on BPA effects on the mammary gland. Her research reveals clear non-monotonic dose response curves, with the administration of lower doses resulting in larger effects on the development of the mammary gland at all-time points.
Cheryl Rosenfeld will assess the recently developed bioinformatics program called mix Omics analyses, which was designed to integrate large ’omics datasets, to integrate data across organs to examine the potential whole-body effects of BPA., Her research indicates that exposure to even a
low dose of BPA currently considered safe by the FDA leads to simultaneous effects in multiple organ systems and at all ages examined.
Gail Prins will then conclude by presenting the integrated findings from seven studies from the Clarity report which showed effects of BPA, including the urethral, ovarian and cardiovascular effects in addition to those overviewed in the webinar. She will then present the key findings from these studies and how the results should be interpreted by regulatory agencies.